Researchers in Japan have achieved a notable success in a Phase 3 clinical trial to determine whether a new vaccine could be more effective than current treatments options.
Developed by Shionongi and Roche, the new drug, Baloxavir, was found to be able to stop the spread of the virus within 24 hours of a patient taking the pill and only requires a single dose to be effective.
In a Phase 3 study produced in October, the treatment was able to alleviate the symptoms of influenza from a median time of 53.7 hours compared with placebo treatment of 80.2 hours.
